COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL

被引：3
|
作者：
Pititto, L. [1 ]
Neslusan, C. [2 ]
Teschemaker, A. R. [2 ]
Johansen, P. [3 ]
Willis, M. [3 ]
Asano, E. [1 ]
Puig, A. [4 ]
机构：
[1] Janssen Cilag Farmaceut Ltda, Sao Paulo, Brazil
[2] Janssen Global Serv LLC, Raritan, NJ USA
[3] Swedish Inst Hlth Econ, Lund, Sweden
[4] Johnson & Johnson Int, New Brunswick, NJ USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.510
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB14
引用
收藏
页码：A864 / A864
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF SITAGLIPTIN COMPARED TO SULPHONYLUREA AS AN ADD-ON TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Athanasakis, K.
    Zhuo, J.
    Chen, J.
    Boubouchairopoulou, N.
    Tarantilis, F.
    Papageorgiou, M.
    Retsa, P.
    Brandtmuller, A.
    Tunceli, K.
    Karokis, A.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2015, 18 (07) : A608 - A608
  • [32] Blood Pressure (BP) Effects of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Pfeifer, Michael
    Townsend, Raymond
    Davies, Michael J.
    Vijapurkar, Ujjwala
    Ren, Jimmy
    DIABETES, 2016, 65 : A303 - A303
  • [33] Time Until Insulin Initiation for Canagliflozin (CANA) vs. Sitagliptin (SITA) in Dual Therapy and Triple Therapy for Type 2 Diabetes Mellitus (T2DM) in the UK
    Schroeder, Melanie
    Chan, Edmond
    Willis, Michael
    Johansen, Pierre
    Nilsson, Andreas
    Schubert, Agata
    Neslusan, Cheryl
    DIABETES, 2016, 65 : A327 - A327
  • [34] Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Sulfonylurea (SU) Monotherapy: A CANVAS Substudy
    Fulcher, Greg
    Matthews, David
    Perkovic, Vlado
    Mahaffey, Kenneth W.
    Weiss, Robert
    Rosenstock, Julio
    Capuano, George
    Desai, Mehul
    Shaw, Wayne
    Vercruysse, Frank
    Meininger, Gary
    Neal, Bruce
    DIABETES, 2013, 62 : A292 - A292
  • [35] Efficacy and Safety of Saxagliptin Add-on to Metformin Compared with Acarbose Add-on to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin Monotherapy
    Du, Jin
    Liang, Li
    Fang, Hui
    Xu, Fengmei
    Li, Wei
    Shen, Liya
    Mu, Yiming
    DIABETES, 2016, 65 : A293 - A293
  • [36] Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
    Charalampos Tzanetakos
    Nicholas Tentolouris
    Georgia Kourlaba
    Nikos Maniadakis
    Clinical Drug Investigation, 2016, 36 : 649 - 659
  • [37] Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
    Tzanetakos, Charalampos
    Tentolouris, Nicholas
    Kourlaba, Georgia
    Maniadakis, Nikos
    CLINICAL DRUG INVESTIGATION, 2016, 36 (08) : 649 - 659
  • [38] Genital Mycotic Infections With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Nyirjesy, Paul
    Sobel, Jack
    Fung, Albert
    Gassmann-Mayer, Cristiana
    Ways, Kirk
    Usiskin, Keith
    DIABETES, 2013, 62 : A276 - A276
  • [39] SOURCES OF LONG-TERM QUALITY ADJUSTED LIFE YEAR (QALY) GAINS FOR CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK SETTING
    Willis, M.
    Johansen, P.
    Schroeder, M.
    Thompson, G.
    Girod, I
    Neslusan, C.
    VALUE IN HEALTH, 2013, 16 (07) : A440 - A441
  • [40] The Role of Estimated Glomerular Filtration Rate (eGFR) in Cost-Effectiveness (CE) Analyses Using Canagliflozin (CANA) vs. Sulfonylurea (SU) to Treat Type 2 Diabetes Mellitus (T2DM)
    Neslusan, Cheryl
    Willis, Michael
    Johansen, Pierre
    Schroeder, Melanie
    Nilsson, Andreas
    Chan, Edmond
    Asseburg, Christian
    Schubert, Agata
    DIABETES, 2016, 65 : A329 - A329
12345